Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Effects of HRS-1780, Henagliflozin, Metformin, and HRS-7535 in Healthy Subjects
NCT06495931Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1780, hengagliflozin + metformin and HRS-7535 in type 2 diabetes mellitus (T2DM), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Time t and 1 more. Started Jul 2024; status: completed.
02
Drugs
HRS-1780hengagliflozin + metforminHRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06495931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495931.